ABSTRACT
O fenômeno de Raynaud (FRy) caracteriza-se por episódios reversíveis de vasoespasmos de extremidades, que ocorrem usualmente após estresse ou exposição ao frio. O FRy pode ser primário ou secundário a uma série de condições, principalmente a doenças do espectro da esclerose sistêmica (ES). Na ES, o FRy costuma ser mais grave, e lesões isquêmicas de extremidades são frequentes. Nos últimos anos, avanços no estudo da fisiopatologia do FRy e da doença vascular na ES propiciaram o surgimento de novas opções terapêuticas para esta manifestação. Os bloqueadores de canal de cálcio devem ser utilizados como tratamento de primeira escolha para o FRy. Novas drogas, como os inibidores da fosfodiesterase V e os prostanoides, podem ser utilizados em pacientes com FRy grave, e a bosentana (antagonista do receptor da endotelina-1) é indicada para a prevenção de úlceras digitais recorrentes.
Raynaud's phenomenon (RP) is characterized by episodic vasospasm of the extremities, usually in response to stress or cold exposure. It can be primary or secondary to several conditions, especially systemic sclerosis-related diseases. In systemic sclerosis (SSc), RP is usually more severe and digital ischemic lesions are a frequent problem. In recent years, advances in the understanding of the pathophysiology of RP and of SSc vasculopathy led to the development of new therapeutic options for this condition. Calcium-channel blockers are the first choice for the treatment of RP. New drugs including phosphodiesterase type V inhibitors and prostanoids can be used for severe RP, and bosentan (endothelin-1 receptor antagonist) for prevention of recurrent digital ulcers.
Subject(s)
Humans , Male , Female , Raynaud Disease/physiopathology , Raynaud Disease/drug therapy , Scleroderma, Systemic/physiopathology , Scleroderma, Systemic/drug therapy , Microscopic Angioscopy/methods , Autoantibodies , Calcium Channel Blockers/therapeutic use , Vascular Diseases/physiopathology , /therapeutic use , Receptors, Endothelin/antagonists & inhibitors , Skin Ulcer/prevention & control , Skin Ulcer/drug therapy , Vasodilator Agents/therapeutic useABSTRACT
En Venezuela se utiliza la inmunoterapia por su bondad terapéutica y operacional en el tratamiento de la leishmaniasis cutánea y se aprecian diferencias de su efectividad entre los servicios locales de salud que la emplean. En el estado Mérida, donde se tiene un bajo nivel de falla terapéutica, se desconocen los factores de riesgo ó de protección que la determinan. Por ello se planteó realizar un estudio epidemiológico de casos y controles para evaluar los factores individuales demográficos, clínicos, inmunológicos y adherencia terapéutica que influyen en dicha efectividad. El ajuste con regresión logística determinó según definición: a) Demográfica: como riesgo las edades extremas, tabaquismo y de oficio doméstico, con protección en el alfabeto educativamente, b) Clínica: como riesgo la forma intermedia, cinco o más lesiones, infección secundaria y ubicación en pié, con protección en la forma localizada y tamaño menor a 60 mm, c) Inmunológica: de riesgo las bajas respuestas a leishmánina y PPD, d) Adherencia terapéutica: son riesgo la aplicación tópica y aseo local inadecuados. Se concluye, hay factores de riesgo y protección que modelan la eficacia de la inmunoterapia, lo que en consecuencia demanda una dinámica vigilancia clínico-epidemiológica para potenciar dicha terapéutica.
Immunotherapy is used in Venezuela as treatment of cutaneous leishmaniasis and there are differences among the health services that use it. In Merida State there are a low proportion of failures, but the factors that are related to this failure are unknown. A case-control study was planned to evaluate the demographics, clinical, immunological factors and the treatment compliance that can be related to the effectiveness. Logistic regression showed that the factors related to failure were: a) demographics: lower and older ages, smoking, domestic labor and illiteracy; b) clinical: intermediate leishmaniasis, five or more lesions, aggregated infection, lesions in feet, and lesion size above 60 mm; c) Immunology: low reactivity to Montenegro and tuberculin tests; d) treatment compliance: use of incorrect topical substances and inadequate cleaning of ulcer. As a conclusion, there are several factors that influence treatment response, that require clinical and epidemiological surveillance to increase the effect of therapy.
Subject(s)
Humans , Male , Female , Leishmaniasis, Cutaneous/epidemiology , Leishmaniasis, Cutaneous/ethnology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/prevention & control , Leishmaniasis, Cutaneous/drug therapy , Immunotherapy , Skin Ulcer/epidemiology , Skin Ulcer/parasitology , Skin Ulcer/prevention & control , Skin Ulcer/drug therapyABSTRACT
The action of an anti-loxosceles serum on in vitro human red blood cell hemolysis and on the development of ulcer-necrotic lesions in rabbit skin, induced by loxosceles laeta venom, was studied. An 81ñ 3 per cent hemolysis was obtained after 72 h incubation of a 2.5 per cent Rh+ red blood cell solution with the equivalent of one Loxosceles laeta venom gland. This parameter was not modified adding anti-loxosceles serum before, along with or after the venom (79.7 ñ 0.8, 77.3 ñ 2.1 and 80.7 ñ 0.7 per cent respectively). After the intradermic injection of a minimal necrotizing venom dose in rabbits, a skin necrotic lesion appeared. This lesion did not appear if anti-loxosceles serum was injected together with the venom; if the serum was injected one hour after the venom, the resulting skin lesion was inflammatory but not necrotic. It is conclude that anti-loxoscles serum does not inhibit loxosceles venom induced hemolysis and causes a time dependent inhibition on skin necrotic lesions
Subject(s)
Animals , Rabbits , Antivenins/therapeutic use , Necrosis/prevention & control , Hemolysis , In Vitro Techniques , Skin Ulcer/prevention & control , Spider Venoms/adverse effects , Spider Bites/therapy , Heparin/therapeutic use , Dapsone/therapeutic useABSTRACT
Micro-cellular rubber (MCR) foot-wear has been used widely over the past several years for the anaesthetic feet of leprosy. Although MCR has got good shock absorbing and moulding qualities, many tend to reject the foot-wear because of the stigma of the disease which it carries. Two newer models of foot-wear which would meet the demands of anaesthetic sole and avoid the stigma because of their resemblance to foot-wear available in the market were tried. Model mark II fulfilled the needs and was acceptable to the patients. Such models must be tried and acceptable and effective foot-wear need to be made available.